^
Association details:
| Biomarker: | KANK1-NTRK2 fusion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel fusion sarcomas including targetable NTRK and ALK
Published date:
07/22/2021
Excerpt:
...novel KANK1-NTRK2 sarcoma of bone and soft tissue with spindled pleomorphic to epithelioid features (AWD metastases). 3) Novel ERC1-ALK unaligned fusion, a low grade infiltrative deep soft tissue hand sarcoma with prominent-vascularity...was successfully treated with ALK-inhibitor (Crizotinib), avoiding amputation...fusion sarcomas include new KANK1-NTRK2 and ERC1-ALK, the latter successfully treated by targeted-therapy.
DOI:
10.1016/j.anndiagpath.2021.151800
